Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Completed Phase 2 Trials for Vosaroxin (DB11999)

Also known as: Myelodysplastic Syndrome With Excess Blasts-2

IndicationStatusPhase
DBCOND0092771 (Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03338348Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2Treatment